Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Semiallogeneic cancer vaccines formulated with granulocyte-macrophage colony-stimulating factor for patients with metastatic gastrointestinal adenocarcinomas: A pilot phase I study
Autore:
Newton, DA; Acierno, PM; Metts, MC; Baron, PL; Brescia, FJ; Gattoni-Celli, S;
Indirizzi:
Med Univ S Carolina, Lab Immunotherapy, Strom Thurmond Biomed Res Ctr, Dept Radiat Oncol, Charleston, SC 29403 USA Med Univ S Carolina Charleston SCUSA 29403 col, Charleston, SC 29403 USA Med Univ S Carolina, Dept Surg, Charleston, SC 29403 USA Med Univ S Carolina Charleston SC USA 29403 urg, Charleston, SC 29403 USA Med Univ S Carolina, Dept Med, Hollings Canc Ctr, Charleston, SC 29403 USAMed Univ S Carolina Charleston SC USA 29403 Ctr, Charleston, SC 29403 USA
Titolo Testata:
JOURNAL OF IMMUNOTHERAPY
fascicolo: 1, volume: 24, anno: 2001,
pagine: 19 - 26
SICI:
1524-9557(200101/02)24:1<19:SCVFWG>2.0.ZU;2-5
Fonte:
ISI
Lingua:
ENG
Soggetto:
SOMATIC HYBRIDS; GENE-TRANSFER; IMMUNITY;
Keywords:
semiallogeneic; hybrids; vaccine; gastrointestinal cancers; granulocyte-macrophage colony-stimulating factor;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
15
Recensione:
Indirizzi per estratti:
Indirizzo: Gattoni-Celli, S Med Univ S Carolina, Lab Immunotherapy, Strom Thurmond Biomed Res Ctr, Dept Radiat Oncol, Room 338,114 Doughty St, Charleston, SC 29403 USA Med Univ S Carolina Room 338,114 Doughty St Charleston SC USA 29403
Citazione:
D.A. Newton et al., "Semiallogeneic cancer vaccines formulated with granulocyte-macrophage colony-stimulating factor for patients with metastatic gastrointestinal adenocarcinomas: A pilot phase I study", J IMMUNOTH, 24(1), 2001, pp. 19-26

Abstract

The authors report the results of a phase I clinical study using semiallogeneic cancer vaccines formulated with granulocyte-macrophage colony-stimulating factor (GM-CSF) to treat patients with metastatic adenocarcinomas of the gastrointestinal tract. A specially engineered cell line, FO1-12, was used to generate semiallogeneic hybrids by fusion with patient-derived tumor cells; the hybrids express HLA class I and II haplotypes derived from both parental cells. For treatment, the vaccine was mixed with GM-CSF, irradiated, and injected intradermally into patients at weekly or biweekly intervals. Vaccinations were associated with minimal or no toxicity and showed that st semiallogeneic hybrids formulated with GM-CSF can induce a specific antitumor immune response in some patients, as measured by a delayed-type hypersensitivity response to autologous tumor cells. Because of the simplicity, Feasibility, and flexibility of this immunotherapeutic approach, semiallogeneic hybrid vaccines have the potential to be used in the treatment of virtually any type of cancer.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 26/01/20 alle ore 22:50:32